Nexalin Technology announces secondary analysis for Alzheimer’s trial data
Nexalin Technology says a new secondary analysis of prior clinical trial data shows unreported improvements in memory, comprehension and language function in Alzheimer’s patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.